[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522161":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":38,"responsibleParty":57,"collaborators":59,"id":63,"slug":18,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":18,"enrollmentInfo":71,"targetDuration":18,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":83,"overallStatus":41,"whyStopped":18,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"University Hospital, Antwerp","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CytoSorb hemoadsorption","ACTIVE_COMPARATOR","Patients with acute on chronic liver failure will receive CytoSorb treatment for 72 hours. The aim is to remove the molecules that drive systemic inflammation.",[13],"Device: CytoSorb",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Historical group that received only standard medical care",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DEVICE","CytoSorb","Application of CytoSorb treatment for 72 hours in patients with ACLF",[9],[26],{"name":27,"affiliation":5,"role":28},"Karolien Dams","PRINCIPAL_INVESTIGATOR",[30,34],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},"CONTACT","+3238215175","Karolien.Dams@uza.be",{"name":35,"role":31,"phone":36,"phoneExt":18,"email":37},"Rita Jacobs","+3238214795","rita.jacobs2@uza.be",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"UZA","RECRUITING","Edegem","Antwerp","2650","Belgium",{"type":47,"coordinates":48},"Point",[49,50],4.44504,51.15662,{"lat":50,"lon":49},[53,55],{"name":54,"role":31,"phone":32,"phoneExt":18,"email":33},"Karolien Dams, MD",{"name":56,"role":31,"phone":36,"phoneExt":18,"email":37},"Rita Jacobs, MD",{"type":28,"investigatorFullName":27,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Principal Investigator, MD, senior staff intensive care",[60],{"name":61,"class":62},"CytoSorbents Europe GmbH","INDUSTRY","100522161",false,"NCT06079021","COOLEY- Study: aCute On chrOnic Liver failurE Using the cYtosorb Device","COOLEY","Inclusion Criteria:\n\n* adult patients (≥ 18 years) admitted to the University Hospital of Antwerp (UZA), Belgium.\n\n  * Written informed consent from patient or if not possible due to encephalopathy (\\> grade 2): legal representative\n  * acute-on-chronic liver failure (ACLF) grade ≥ 2:\n\n    * Acute decompensation event (identifiable trigger)\n    * Hepatic encephalopathy grade ≥ 2\n    * Acute kidney injury (AKI) according to Kidney Disease: Improving Global Outcome (KDIGO) criteria stage 3 (≥ 3-fold increase of serum creatinine OR increase of serum creatinine to ≥ 4 mg\u002Fdl OR urine output ≤ 0.3 ml\u002Fkg\u002Fh for ≥ 24 hours OR anuria for ≥ 12 hours)\n    * Serum bilirubin ≥ 10 mg\u002Fdl\n    * Hemodynamic instability with vasopressor support (norepinephrine \\> 0.05 mcg\u002Fkg\u002Fmin)\n\nExclusion Criteria:\n\n* • known patient will against participation in the study or against the measures applied in the study\n\n  * a decision made prior to inclusion to stop further treatment of the patient within the next 24 hours\n  * no complete remission of malignancy including hepatocellular carcinoma within the past 12 months\n  * ongoing intermittent or CRRT before study inclusion","ALL","18 Years",{"count":72,"type":73},20,"ESTIMATED","INTERVENTIONAL",[76],"NA","A Prospective, Single-Center trial, in Patients With Acute on Chronic Liver Failure. Study of Standard Medical Care Plus CytoSorb® Compared to Standard Medical Care Alone in a historical group.",[79,80,81,82],"Acute-On-Chronic Liver Failure","Anticoagulant Adverse Reaction","Sarcopenia","Ultrasonography",[84,85,86,87,88,89,90,91],"acute on chronic liver failure","sarcopenia","citrate anticoagulation","low molecular weight heparins","hand grip strength","skeletal muscle ultrasound","hemoadsorption","CRRT","2026-04-27",{"date":94,"type":95},"2026-05-01","ACTUAL",{"date":97,"type":95},"2024-06-08",{"date":99,"type":73},"2027-12-31",{"name":5,"class":6},1]